Abstract. Loss of a section of the long arm of chromosome 5, as a sole cytogenetic abnormality, characterizes a rare type of myelodysplastic syndrome [del(5q) MDS] and the co-existence of the JAK2 V617F mutation occurs in a small subset of these cases. Patients with isolated del(5q) MDS have a relatively favorable prognosis, with transformation to acute myeloid leukemia occurring in <10%, and their disease responds well to lenalidomide. However the optimal therapeutic approach for patients with del(5q) MDS in coexistence with the JAK2 V617F mutation, which is common to myeloproliferative neoplasms, remains to be elucidated. The present study reports a 77-year-old, transfusion-dependent female patient diagnosed with del(5q) MDS and a concomitant JAK2 V617F mutation. The patient was started on 10 mg lenalidomide daily for 21 days in a 28 day-cycle and within the first month of treatment, the patient became transfusion-independent. The only toxicity observed was grade 3 neutropenia, which was managed with transient treatment discontinuation and dose reduction on restart (5 mg). The patient achieved a complete cytogenetic and molecular response (normal karyotype and undetected JAK2 V617F mutation) within 6 months of treatment. However, 12 months post treatment initiation and while on hematological, cytogenetic and molecular response, the patient was unwilling to continue on treatment and lenalidomide was discontinued. The patient remains in hematological response, which lasts for >5 years despite treatment discontinuation. The present case highlights the coexistence of the JAK2 V617F mutation in del(5q) MDS and suggests that lenalidomide treatment is beneficial and effective for these patients, leading to complete hematological, cytogenetic and molecular response. Hematological response may be sustained for long periods of time, even following the discontinuation of the treatment.
Introduction
Deletion of the long arm of chromosome 5 is the most common cytogenetic abnormality in patients with myelodysplastic syndrome (MDS), occurring in ~15% of cases (1) . However, loss of the chromosome 5q31.3 to 5q33.3 region, as a sole chromosomal abnormality, is observed in 5% of MDS patients and characterizes del(5q) MDS, which is a clonal stem cell disorder (2) . This MDS subtype has a favorable prognosis with transformation to acute myeloid leukemia occurring in <10% of the cases and it responds well to lenalidomide treatment (3) .
The JAK2 V617F mutation is present in the majority of patients with myeloproliferative neoplasms (MPN): >90% of patients with polycythemia vera, and 50% of patients with primary myelofibrosis and essential thrombocythemia (ET) (4) . The presence of this mutation has also been described in other hematological malignancies, however, to a much lesser extent; ~3-5% of patients with MDS and <5% of patients with acute myeloid leukemia (AML) (5) . The coexistence of del(5q) as sole cytogenetic abnormality and the JAK2 V617F mutation is even rarer occurring in a small subset of del(5q) MDS cases, and the optimal therapeutic approach in these patients remains to be elucidated (6) .
The present study reports the case of a patient with del(5q) MDS and a concomitant JAK2 V617F mutation, who achieved complete cytogenetic and molecular remission with lenalidomide and enjoyed durable hematological response that lasts for >5 years post treatment discontinuation.
Case report
A 77-year-old female patient was referred to severe eosinophilia, and thrombocytosis (platelets, 774x10 9 /l). In the peripheral blood smear basophilic stippling and megaloblastoid changes of erythrocytes were observed. The biochemical tests were unremarkable, with the exception of increased levels of lactic dehydrogenase. On clinical examination, mild hepatosplenomegaly was observed, which was confirmed by ultrasound scan.
The patient underwent diagnostic assessments to exclude infections, connective tissue disorders and cancer. These assessments were negative. Computer tomography of the abdomen revealed mild hepatosplenomegaly. At this point bone marrow aspiration and biopsy were performed. Karyotyping and molecular analysis were also performed for the presence of bcr-abl chimeric transcript and JAK2 V617F mutation, and also FIP1L1/PDGFRA and TEL/PDGFRB rearrangements, considering MPN as the most likely diagnosis.
The bone marrow aspirate revealed increased cellularity, myeloid lineage hyperplasia with a left shift and increased numbers of hypolobated megakaryocytes, compatible with a MPN. Molecular analyses were positive for the presence of the JAK2 V617F mutation and negative for the presence of bcr-abl transcript. Pending the results from the trephine biopsy and karyotyping, and on the basis of MPN being the most possible diagnosis, either ET or the cellular phase of primary myelofibrosis, a clinical decision was made to initiate treatment. The patient was started on interferon-α, low-dose aspirin and recombinant erythropoietin as a result of a constant requirement for blood transfusions and her age, which defined her as a high-risk patient. A month later, WBC count and platelets were normalized, however, the patient remained transfusion-dependent, requiring at least two packed red blood cell units per month.
One month later, the results of karyotyping and the trephine biopsy were acquired. The latter was reported as having increased cellularity (95%) with concomitant hypoplasia of the erythroid lineage; the myeloid lineage was hyperplastic with a left shift and the megakaryocytes were increased in number, decreased in size and their nuclei were hypolobulated, while micromegakaryocytes were also observed (Fig. 1 ). An abnormal karyotype was observed in all twenty metaphases that showed a deletion of the long arm of chromosome 5, involving the chromosome region 5q13-5q33 [46, XX, del (5) (q13 q33)], as the sole cytogenetic abnormality.
Therefore, the diagnosis, according to the WHO classification of hematologic neoplasms (7), was MDS with an isolated deletion of 5q chromosome and a concomitant JAK2 V617F mutation, categorizing her to the low risk group, according to the International Prognostic Scoring System (anemia, blasts <5%, favorable karyotype) (8) . On the basis of definite diagnosis, previous therapy was discontinued and the patient was initiated on 10 mg lenalidomide daily for 21 days in a 28-day-cycle since the patient was transfusion-dependent.
Within the first month of treatment the patient became transfusion-independent. The only toxicity observed was grade 3 neutropenia, and was managed by treatment withhold until resolution and one dose level reduction on restart (5 mg). On lenalidomide (5 mg) in cycles of 21/28 days, the patient achieved both cytogenetic and molecular complete response (normal karyotype and undetected JAK2 V617F mutation) within 6 months of treatment (Fig. 2) and remained transfusion-independent, maintaining hemoglobin levels of ~15 g/dl for the next 6 months. However, 12 months post-treatment initiation and while on hematological, cytogenetic and molecular response, the patient was unwilling to continue with treatment and lenalidomide was discontinued. The patient remained in complete response for a further 23 months when a new bone marrow aspirate and cytogenetic analysis was performed and the karyotype of the diagnosis [46, XX, del (5) (q13 q33)] re-occurred, but in one of the twenty-four metaphases examined. However, the patient preserved the hematological and molecular response, and the transfusion-independency, therefore, treatment was not re-initiated. Currently, 70 months following diagnosis and 55 months without treatment, the patient is in excellent condition and transfusion-independent, maintaining a hematocrit level of 42%.
Discussion
Approximately 5% of MDS patients present with isolated del(5q), characterized by severe anemia, preserved or even elevated platelet count and high response rates to lenalidomide (3). The concomitant presence of the 5q deletion and a JAK2 V617F mutation in MDS was first shown in 6/97 patients with MDS with the 5q deletion (6) . Patients harboring the JAK2 V617F mutation compared to those without the mutation, presented with hypercellular bone marrow and exhibited significantly higher levels of WBC count and a trend towards higher levels of platelet count (6) . Since the clinical outcome of this subset of patients remains unclear, the 2008 WHO classification classifies them as MDS with isolated del(5q), rather than in the MDS/MPN category. Therefore, more data collection from patients with such characteristics are required in order to draw clear conclusions.
The present patient was diagnosed with isolated del(5q) MDS and a concurrent JAK2 V617F mutation. Lenalidomide was administered and the patient achieved transfusion-independence within 4 weeks of treatment initiation, and complete cytogenetic and molecular response within 6 months. The patient remains transfusion-independent for the last 70 months, despite lenalidomide discontinuation after 12 months of therapy. The del(5q) clone reappeared 23 months later in 1/24 metaphases, however, without clinical effects.
Beneficial treatment with lenalidomide in isolated del(5q) and a concomitant JAK2 V617F mutation has been previously reported in three MDS patients (9-11) and one patient with AML arising from JAK2 V617F and del(5q) MDS. It remains unclear whether the lenalidomide effect has a suppressive role against del(5q) cells and another independent activity against the JAK2 V617F mutated clone (10) , since it has not been delineated whether the two genetic abnormalities involve the same or two distinct hematopoietic clones. Sokol et al (12) investigated the clonal origin of the JAK2 V617F mutation in a patient with del(5q) MDS presenting with thrombocytosis and normal hemoglobin, and suggested that the latter is the case.
Currently, the recommendation regarding lenalidomide treatment in MDS del(5q) patients is to treat until disease progression (13) . Although it was recently shown that lenalidomide treatment in MDS del(5q) patients does not appear to increase the risk to AML transformation (14) , other long-term effects of immunomodulation have not been elucidated and one could argue that intermittent use of lenalidomide may be prudent is certain cases. The present case indicated that durable hematological response may be sustained despite discontinuation of lenalidomide, whereas others have shown that re-challenge may also be safe and feasible, albeit with no profound cytogenetic response (15) . However, in order to draw safe conclusions regarding the treatment duration and time of discontinuation, a randomized clinical trial is required to compare continuous treatment until progression, vs. treatment discontinuation after having achieved sustained complete cytogenetic response.
In conclusion, the present case highlights the coexistence of a JAK2 V617F mutation in del(5q) MDS and suggests that lenalidomide treatment is beneficial and effective for this subset of patients, leading to complete cytogenetic and molecular response, while durable hematological response may be sustained even following the discontinuation of the treatment. 
